董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudia Grimaldi | 女 | Vice President, Principal Financial Officer, Chief Compliance Officer and Director | 54 | 25.90万美元 | 44.40 | 2025-10-10 |
| James Moran | 男 | Independent Director | 80 | 4.30万美元 | 未持股 | 2025-10-10 |
| Terry L. Lierman | 男 | Independent Director | 77 | 未披露 | 未持股 | 2025-10-10 |
| Ram Mukunda | 男 | President, Chief Executive Officer and Director | 66 | 56.80万美元 | 266.87 | 2025-10-10 |
| Richard Prins | 男 | Chairman of the Board | 68 | 7.50万美元 | 26.80 | 2025-10-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudia Grimaldi | 女 | Vice President, Principal Financial Officer, Chief Compliance Officer and Director | 54 | 25.90万美元 | 44.40 | 2025-10-10 |
| Ram Mukunda | 男 | President, Chief Executive Officer and Director | 66 | 56.80万美元 | 266.87 | 2025-10-10 |
董事简历
中英对照 | 中文 | 英文- Claudia Grimaldi
-
副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
Claudia Grimaldi,has served on the Board of Directors since August 18, 2023 and is the Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with Securities and Exchange Commission ("SEC") filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of IGC Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. She also completed her certification program of the National Association of Corporate Directors . She is also fluent in both English and Spanish. - 副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
- Claudia Grimaldi,has served on the Board of Directors since August 18, 2023 and is the Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with Securities and Exchange Commission ("SEC") filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of IGC Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. She also completed her certification program of the National Association of Corporate Directors . She is also fluent in both English and Spanish.
- James Moran
-
James Moran，自2022年1月起担任Igc Pharma，Inc.的独立董事。他在弗吉尼亚州第8国会选区服务了24年，在那里他被称为“问题解决者”。在他的整个任期内，他展示了两党的领导力，并在两党之间努力寻找共同立场，以解决复杂的问题。他曾在拨款、银行、财务和预算委员会任职。他在国防、卫生和环境领域发挥了领导作用。在国会任职的24年里，莫兰议员被公认为医疗保健和国家安全、环境保护和可持续性、国际贸易和财政责任等领域创新研发的倡导者。他升任拨款委员会的高级领导，使他得以将数十亿美元带入他在北弗吉尼亚的亚历山大、阿灵顿和费尔法克斯县的社区。在当选公职35年后退休的莫兰议员现在供职于一家大型律师事务所，代表国防、科技、娱乐和国际外交领域的国际和国内客户。他还在几个非盈利基金会担任领导职务，也是政府区块链协会的成员。莫兰议员在匹兹堡大学公共与国际事务研究生院获得公共管理硕士学位，在圣十字学院获得经济学学士学位。
James Moran,has served on the Board as an Independent Director since January 2022. He served on Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance, and Budget committees. He played a leadership role in the areas of defense, health, and the environment.He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master's Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelor's in Economics from the College of the Holy Cross. - James Moran，自2022年1月起担任Igc Pharma，Inc.的独立董事。他在弗吉尼亚州第8国会选区服务了24年，在那里他被称为“问题解决者”。在他的整个任期内，他展示了两党的领导力，并在两党之间努力寻找共同立场，以解决复杂的问题。他曾在拨款、银行、财务和预算委员会任职。他在国防、卫生和环境领域发挥了领导作用。在国会任职的24年里，莫兰议员被公认为医疗保健和国家安全、环境保护和可持续性、国际贸易和财政责任等领域创新研发的倡导者。他升任拨款委员会的高级领导，使他得以将数十亿美元带入他在北弗吉尼亚的亚历山大、阿灵顿和费尔法克斯县的社区。在当选公职35年后退休的莫兰议员现在供职于一家大型律师事务所，代表国防、科技、娱乐和国际外交领域的国际和国内客户。他还在几个非盈利基金会担任领导职务，也是政府区块链协会的成员。莫兰议员在匹兹堡大学公共与国际事务研究生院获得公共管理硕士学位，在圣十字学院获得经济学学士学位。
- James Moran,has served on the Board as an Independent Director since January 2022. He served on Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance, and Budget committees. He played a leadership role in the areas of defense, health, and the environment.He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master's Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelor's in Economics from the College of the Holy Cross.
- Terry L. Lierman
-
Terry L. Lierman，自2024年3月起担任董事会独立董事。Lierman先生目前是人类病毒学研究所（IHV）顾问委员会的联合主席，该研究所是美国的一个中心，专注于加速发现致命病毒和免疫疾病的诊断和治疗方法，也是他的母校威斯康星大学拉福莱特公共事务学院访问委员会的成员。Lierman先生创立了儿童研究所（美国顶级儿童研究项目之一）、胰腺癌行动网络（PanCAN）和全国胎儿酒精综合征组织（NOFAS）。此外，从1987年到1999年，他担任the NY life - pillar Funds的董事/受托人。他杰出的职业生涯包括任职于美国国立卫生研究院（“NIH”），担任国家癌症研究所（“NCI”）药物研发的首席管理员，担任美国参议院拨款委员会的工作人员主任，以及白宫与美国众议院多数党领袖的联络主任。
Terry L. Lierman,has served on the Board as an Independent Director since March 2024. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology ("IHV"), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Mr. Lierman founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network ("PanCAN"), and the National Organization on Fetal Alcohol Syndrome ("NOFAS"). In addition, from 1987 to 1999, he served as a director/trustee of the NY Life-Mainstay Funds. His distinguished career includes serving at the National Institutes of Health ("NIH"), as the chief administrator for drug research and development at the National Cancer Institute ("NCI"), and as the Staff Director for the Committee on Appropriations at the U.S. Senate and the Chief of Staff and White House liaison to the U.S. House of Representative's Majority Leader. - Terry L. Lierman，自2024年3月起担任董事会独立董事。Lierman先生目前是人类病毒学研究所（IHV）顾问委员会的联合主席，该研究所是美国的一个中心，专注于加速发现致命病毒和免疫疾病的诊断和治疗方法，也是他的母校威斯康星大学拉福莱特公共事务学院访问委员会的成员。Lierman先生创立了儿童研究所（美国顶级儿童研究项目之一）、胰腺癌行动网络（PanCAN）和全国胎儿酒精综合征组织（NOFAS）。此外，从1987年到1999年，他担任the NY life - pillar Funds的董事/受托人。他杰出的职业生涯包括任职于美国国立卫生研究院（“NIH”），担任国家癌症研究所（“NCI”）药物研发的首席管理员，担任美国参议院拨款委员会的工作人员主任，以及白宫与美国众议院多数党领袖的联络主任。
- Terry L. Lierman,has served on the Board as an Independent Director since March 2024. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology ("IHV"), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Mr. Lierman founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network ("PanCAN"), and the National Organization on Fetal Alcohol Syndrome ("NOFAS"). In addition, from 1987 to 1999, he served as a director/trustee of the NY Life-Mainstay Funds. His distinguished career includes serving at the National Institutes of Health ("NIH"), as the chief administrator for drug research and development at the National Cancer Institute ("NCI"), and as the Staff Director for the Committee on Appropriations at the U.S. Senate and the Chief of Staff and White House liaison to the U.S. House of Representative's Majority Leader.
- Ram Mukunda
-
Ram Mukunda，自成立以来历任创始人、董事、首席执行官、总裁等职务。他负责一般管理，在过去11年中，主要负责公司在医药行业的战略和定位。在加入IGC之前，1990年1月至2004年5月，Mukunda先生担任Startec Global Communications的创始人兼首席执行官。在Startec之前，他曾在通信卫星服务提供商IntelSat担任战略规划顾问，在此之前，曾在华尔街一家精品公司的债券市场工作。Mukunda先生担任马里兰大学工程学院访客委员会的名誉成员。2001年至2003年，他是哈佛大学肯尼迪政府学院、贝尔费尔科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学国际年度校友奖、2001年杰出工程校友奖以及1998年安永会计师事务所年度企业家奖。他拥有美国马里兰大学电气工程学士学位、数学学士学位和工程学硕士学位。Mukunda先生广泛旅行并管理欧洲和亚洲的公司。他拥有超过25年的管理上市公司的经验，收购和整合了20多家公司。
Ram Mukunda,has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the past 11 years, has been largely responsible for the Company's strategy and positioning in the pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider, and prior to that, worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards, including, among others, the 2013 University of Maryland's International Alumnus of the Year Award, the 2001 Distinguished Engineering Alumnus Award, and the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies in Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies. - Ram Mukunda，自成立以来历任创始人、董事、首席执行官、总裁等职务。他负责一般管理，在过去11年中，主要负责公司在医药行业的战略和定位。在加入IGC之前，1990年1月至2004年5月，Mukunda先生担任Startec Global Communications的创始人兼首席执行官。在Startec之前，他曾在通信卫星服务提供商IntelSat担任战略规划顾问，在此之前，曾在华尔街一家精品公司的债券市场工作。Mukunda先生担任马里兰大学工程学院访客委员会的名誉成员。2001年至2003年，他是哈佛大学肯尼迪政府学院、贝尔费尔科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学国际年度校友奖、2001年杰出工程校友奖以及1998年安永会计师事务所年度企业家奖。他拥有美国马里兰大学电气工程学士学位、数学学士学位和工程学硕士学位。Mukunda先生广泛旅行并管理欧洲和亚洲的公司。他拥有超过25年的管理上市公司的经验，收购和整合了20多家公司。
- Ram Mukunda,has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the past 11 years, has been largely responsible for the Company's strategy and positioning in the pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider, and prior to that, worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards, including, among others, the 2013 University of Maryland's International Alumnus of the Year Award, the 2001 Distinguished Engineering Alumnus Award, and the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies in Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies.
- Richard Prins
-
Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
Richard Prins,has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated ("FBW"). Mr. Prins served in a consulting role for RBC until January 2009. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting, and internal controls over financial reporting. - Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
- Richard Prins,has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated ("FBW"). Mr. Prins served in a consulting role for RBC until January 2009. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting, and internal controls over financial reporting.
高管简历
中英对照 | 中文 | 英文- Claudia Grimaldi
副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
Claudia Grimaldi,has served on the Board of Directors since August 18, 2023 and is the Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with Securities and Exchange Commission ("SEC") filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of IGC Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. She also completed her certification program of the National Association of Corporate Directors . She is also fluent in both English and Spanish.- 副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
- Claudia Grimaldi,has served on the Board of Directors since August 18, 2023 and is the Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with Securities and Exchange Commission ("SEC") filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of IGC Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. She also completed her certification program of the National Association of Corporate Directors . She is also fluent in both English and Spanish.
- Ram Mukunda
Ram Mukunda，自成立以来历任创始人、董事、首席执行官、总裁等职务。他负责一般管理，在过去11年中，主要负责公司在医药行业的战略和定位。在加入IGC之前，1990年1月至2004年5月，Mukunda先生担任Startec Global Communications的创始人兼首席执行官。在Startec之前，他曾在通信卫星服务提供商IntelSat担任战略规划顾问，在此之前，曾在华尔街一家精品公司的债券市场工作。Mukunda先生担任马里兰大学工程学院访客委员会的名誉成员。2001年至2003年，他是哈佛大学肯尼迪政府学院、贝尔费尔科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学国际年度校友奖、2001年杰出工程校友奖以及1998年安永会计师事务所年度企业家奖。他拥有美国马里兰大学电气工程学士学位、数学学士学位和工程学硕士学位。Mukunda先生广泛旅行并管理欧洲和亚洲的公司。他拥有超过25年的管理上市公司的经验，收购和整合了20多家公司。
Ram Mukunda,has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the past 11 years, has been largely responsible for the Company's strategy and positioning in the pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider, and prior to that, worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards, including, among others, the 2013 University of Maryland's International Alumnus of the Year Award, the 2001 Distinguished Engineering Alumnus Award, and the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies in Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies.- Ram Mukunda，自成立以来历任创始人、董事、首席执行官、总裁等职务。他负责一般管理，在过去11年中，主要负责公司在医药行业的战略和定位。在加入IGC之前，1990年1月至2004年5月，Mukunda先生担任Startec Global Communications的创始人兼首席执行官。在Startec之前，他曾在通信卫星服务提供商IntelSat担任战略规划顾问，在此之前，曾在华尔街一家精品公司的债券市场工作。Mukunda先生担任马里兰大学工程学院访客委员会的名誉成员。2001年至2003年，他是哈佛大学肯尼迪政府学院、贝尔费尔科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学国际年度校友奖、2001年杰出工程校友奖以及1998年安永会计师事务所年度企业家奖。他拥有美国马里兰大学电气工程学士学位、数学学士学位和工程学硕士学位。Mukunda先生广泛旅行并管理欧洲和亚洲的公司。他拥有超过25年的管理上市公司的经验，收购和整合了20多家公司。
- Ram Mukunda,has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the past 11 years, has been largely responsible for the Company's strategy and positioning in the pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider, and prior to that, worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards, including, among others, the 2013 University of Maryland's International Alumnus of the Year Award, the 2001 Distinguished Engineering Alumnus Award, and the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies in Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies.